ONL Therapeutics
https://www.onltherapeutics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From ONL Therapeutics
Venture Funding Deals: $65m For Iterum's Antibiotic; Genoa's IPF Drug Nets $62m
Iterum Therapeutics and Genoa Pharmaceuticals topped the list of biopharmaceutical start-up firms closing new venture capital rounds in May with $65m and $62m, respectively, to advance drug candidates for bacterial infections and idiopathic pulmonary fibrosis.
Start-Up Previews (10/2011)
This Month's Profile Group: The New Ophthalmic Drug Players, features profiles of Imagen Biotech, KalVista Pharmaceuticals, ONL Therapeutics and Xcovery Vision. Plus these Start-Ups Across Health Care: Acetylon Pharmaceuticals, Aleva Neurotherapeutics, cermaVEIN and Flex Biomedical.
ONL Therapeutics LLC
ONL Therapeutics LLC is developing an experimental drug to preserve sight in people with detached retinas and other retinal disorders. The start-up aims to leverage understanding about FAS, a cell-based receptor that is a key cause of cell death in photoreceptors. ONL’s small peptide is designed to block the FAS receptor on cells of the eye, to keep the natural ligand from binding and keep the cells alive.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice